✦ LIBER ✦

Pivotal studies of orphan drugs approved for neurological diseases

✍ Scribed by Jun Mitsumoto; E. Ray Dorsey; Christopher A. Beck; Karl Kieburtz; Robert C. Griggs

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 100 KB
Volume: 66
Category: Article
ISSN: 0364-5134
DOI: 10.1002/ana.21676

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Profiling of endogenous peptides as a to

Profiling of endogenous peptides as a tool for studying development and neurological disease

✍ J. Randall Slemmon; Thomas M. Wengenack; Dorothy G. Flood 📂 Article 📅 1997 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 124 KB 👁 1 views

The use of a method to follow changes in endogenous peptide production, as they occur in biological studies, is an excellent complement to other molecular techniques. It has the unique ability to characterize peptides that have been produced from protein precursors, and instrumentation is available

Establishment of a HPLC method for precl

Establishment of a HPLC method for preclinical pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rats

✍ Li-bo Li; Jin-lan Zhang; Yu-xiang Wang; Huai-ling Wei; Geng-tao Liu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views

Ofatumumab, a human anti-CD20 monoclonal

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

✍ Mikkel Østergaard; Bo Baslund; William Rigby; Bernadette Rojkovich; Christian Jo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB 👁 2 views